2,8-dihydroxyadenine has been researched along with sodium benzoate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, H; Itoh, T; Kanda, T; Oshima, Y; Sasabe, J; Tajima, T; Uchiyama, K; Wakino, S; Yasui, M; Yoshimoto, K | 1 |
1 other study(ies) available for 2,8-dihydroxyadenine and sodium benzoate
| Article | Year |
|---|---|
Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression.
Topics: Animals; Humans; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; NF-kappa B; Renal Insufficiency, Chronic; Sodium Benzoate; Tumor Necrosis Factor-alpha | 2023 |